AIMS Molecular Science, 2015, 2(2): 77-100. doi: 10.3934/molsci.2015.2.77 Research article Special Issues

Export file:

Format

RIS(for EndNote,Reference Manager,ProCite)
BibTex
Text

Content

Citation Only
Citation and Abstract

Glutamate/NMDA excitotoxicity and HMGB1/TLR4 neuroimmune toxicity converge as components of neurodegeneration

Jian Zou, Fulton T. Crews

Bowles Center For Alcohol Studies, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA

Received date: , Accepted date: , Published date:

Special Issues: Molecular Mechanisms of Neurodegenerative Diseases

Abstract Full Text(HTML) Figure/Table Related pages

Neurodegeneration in brain is linked to both excitotoxicity and neuroimmune gene induction,although the mechanisms are poorly understood. High-mobility group box 1 (HMGB1) is a cytokine like molecule released in brain by glutamate that has been found to enhance neuronal excitability through Toll-like receptor 4 (TLR4). To explore the role of HMGB1 in glutamate/NMDA excitotoxicity or neuroimmune-induced neurodegeneration we used an ex vivo model of organotypic hippocampal-entorhinal cortex (HEC) slice culture. Concentration response and time course studies find release of HMGB1 precedes neuronal death induced by glutamate,NMDA,TNFα and LPS. Blockade of glutamate receptors with antagonist MK-801 prevents glutamate/NMDA stimulation release of HMGB1 and neuronal death as well as blocking neuroimmune (LPS and TNFα) induced neuronal death. Similarly,HMGB1 neutralizing antibodies or inhibitor glycyrrhizin block glutamate/NMDA as well as neuroimmune (LPS and TNFα) induced neuronal death. Further,delayed neuronal cell death mediated by LPS and TNFα was rescued by NR2B inhibitor ifenprodil. Together,these findings suggest HMGB1 contributes a critical element of both glutamate/NMDA as well as neuroimmune induced neurodegeneration indicating HMGB1 may be a novel target crossing multiple neurodegeneration pathologies.

Figure/Table

Supplementary

Article Metrics

References

1. Mattson MP (2000) Apoptosis in neurodegenerative disorders. Nat Rev Mol Cell Biol 1: 120-129.

2. Bredesen DE, Rao RV, Mehlen P (2006) Cell death in the nervous system. Nature 443: 796-802.

3. Qin L, Wu X, Block ML, et al. (2007) Systemic LPS causes chronic neuroinflammation and progressive neurodegeneration. Glia 55: 453-462.

4. Tilleux S, Hermans E (2007) Neuroinflammation and regulation of glial glutamate uptake in neurological disorders. J Neurosci Res 85: 2059-2070.

5. Sheldon AL, Robinson MB (2007) The role of glutamate transporters in neurodegenerative diseases and potential opportunities for intervention. Neurochem Int 51: 333-355.

6. Kostic M, Zivkovic N, Stojanovic I (2013) Multiple sclerosis and glutamate excitotoxicity. Rev Neurosci 24: 71-88.

7. Morimoto K, Murasugi T, Oda T (2002) Acute neuroinflammation exacerbates excitotoxicity in rat hippocampus in vivo. Exp Neurol 177: 95-104.

8. Zou JY, Crews FT (2005) TNF alpha potentiates glutamate neurotoxicity by inhibiting glutamate uptake in organotypic brain slice cultures: neuroprotection by NF kappa B inhibition. Brain Res 1034: 11-24.

9. Scaffidi P, Misteli T, Bianchi ME (2002) Release of chromatin protein HMGB1 by necrotic cells triggers inflammation. Nature 418: 191-195.

10. Bell CW, Jiang W, Reich CF, et al. (2006) The extracellular release of HMGB1 during apoptotic cell death. Am J Physiol Cell Physiol 291: C1318-1325.

11. Zou JY, Crews FT (2014) Release of neuronal HMGB1 by Ethanol through decreased HDAC activity activates brain neuroimmune signaling. PloS One 9: e87915.

12. Evankovich J, Cho SW, Zhang R, et al. (2010) High mobility group box 1 release from hepatocytes during ischemia and reperfusion injury is mediated by decreased histone deacetylase activity. J Biol Chem 285: 39888-39897.

13. Lotze MT, Tracey KJ (2005) High-mobility group box 1 protein (HMGB1): nuclear weapon in the immune arsenal. Nat Rev Immunol 5: 331-342.

14. Andersson U, Tracey KJ (2011) HMGB1 is a therapeutic target for sterile inflammation and infection. Annu Rev Immunol 29: 139-162.

15. Tang D, Billiar TR, Lotze MT (2012) A Janus tale of two active high mobility group box 1 (HMGB1) redox states. Mol Med 18: 1360-1362.

16. Janko C, Filipovic M, Munoz LE, et al. (2014) Redox modulation of HMGB1-related signaling. Antioxid Redox Signal 20: 1075-1085.

17. Magna M, Pisetsky DS (2014) The role of HMGB1 in the pathogenesis of inflammatory and autoimmune diseases. Mol Med 20: 138-146.

18. Faraco G, Fossati S, Bianchi ME, et al. (2007) High mobility group box 1 protein is released by neural cells upon different stresses and worsens ischemic neurodegeneration in vitro and in vivo. J Neurochem 103: 590-603.

19. Kim JB, Sig Choi J, Yu YM, et al. (2006) HMGB1, a novel cytokine-like mediator linking acute neuronal death and delayed neuroinflammation in the postischemic brain. J Neurosci 26: 6413-6421.

20. Lo Coco D, Veglianese P, Allievi E, et al. (2007) Distribution and cellular localization of high mobility group box protein 1 (HMGB1) in the spinal cord of a transgenic mouse model of ALS. Neurosci Lett 412: 73-77.

21. Crews FT, Qin L, Sheedy D, et al. (2012) High Mobility Group Box 1/Toll-like Receptor Danger Signaling Increases Brain Neuroimmune Activation in Alcohol Dependence. Biol Psychiatry 73: 602-612.

22. Maroso M, Balosso S, Ravizza T, et al. (2010) Toll-like receptor 4 and high-mobility group box-1 are involved in ictogenesis and can be targeted to reduce seizures. Nat Med 16: 413-419.

23. Kim SW, Jin Y, Shin JH, et al. (2012) Glycyrrhizic acid affords robust neuroprotection in the postischemic brain via anti-inflammatory effect by inhibiting HMGB1 phosphorylation and secretion. Neurobiol Dis 46: 147-156.

24. Ohnishi M, Katsuki H, Fukutomi C, et al. (2011) HMGB1 inhibitor glycyrrhizin attenuates intracerebral hemorrhage-induced injury in rats. Neuropharmacology 61: 975-980.

25. Okuma Y, Liu K, Wake H, et al. (2014) Glycyrrhizin inhibits traumatic brain injury by reducing HMGB1-RAGE interaction. Neuropharmacology 85: 18-26.

26. Chavan SS, Huerta PT, Robbiati S, et al. (2012) HMGB1 mediates cognitive impairment in sepsis survivors. Molecular medicine 18: 930-937.

27. Brana C, Benham C, Sundstrom L (2002) A method for characterising cell death in vitro by combining propidium iodide staining with immunohistochemistry. Brain Res Brain Res Protoc 10: 109-114.

28. Noraberg J, Kristensen BW, Zimmer J (1999) Markers for neuronal degeneration in organotypic slice cultures. Brain Res Brain Res Protoc 3: 278-290.

29. Zimmer J, Kristensen BW, Jakobsen B, et al. (2000) Excitatory amino acid neurotoxicity and modulation of glutamate receptor expression in organotypic brain slice cultures. Amino Acids 19: 7-21.

30. Koh JY, Choi DW (1987) Quantitative determination of glutamate mediated cortical neuronal injury in cell culture by lactate dehydrogenase efflux assay. J Neurosci Methods 20: 83-90.

31. Zou JY, Crews FT (2005) TNF alpha potentiates glutamate neurotoxicity by inhibiting glutamate uptake in organotypic brain slice cultures: neuroprotection by NF kappa B inhibition. Brain Res 1034: 11-24.

32. Balosso S, Liu J, Bianchi ME, et al. (2014) Disulfide-Containing High Mobility Group Box-1 Promotes N-Methyl-d-Aspartate Receptor Function and Excitotoxicity by Activating Toll-Like Receptor 4-Dependent Signaling in Hippocampal Neurons. Antioxid Redox Signal 21: 1726-1740.

33. Chenard BL, Menniti FS (1999) Antagonists selective for NMDA receptors containing the NR2B subunit. Curr Pharma Des 5: 381-404.

34. Kim SW, Lim CM, Kim JB, et al. (2011) Extracellular HMGB1 released by NMDA treatment confers neuronal apoptosis via RAGE-p38 MAPK/ERK signaling pathway. Neurotox Res 20: 159-169.

35. Glass CK, Saijo K, Winner B, et al. (2010) Mechanisms underlying inflammation in neurodegeneration. Cell 140: 918-934.

36. Crews FT, Qin L, Sheedy D, et al. (2013) High mobility group box 1/Toll-like receptor danger signaling increases brain neuroimmune activation in alcohol dependence. Biol Psychiatry 73: 602-612.

37. Kim JB, Lim CM, Yu YM, et al. (2008) Induction and subcellular localization of high-mobility group box-1 (HMGB1) in the postischemic rat brain. J Neurosci Res 86: 1125-1131.

38. Qiu J, Nishimura M, Wang Y, et al. (2008) Early release of HMGB-1 from neurons after the onset of brain ischemia. J Cereb Blood Flow Metab 28: 927-938.

39. Choi DW (1987) Ionic dependence of glutamate neurotoxicity. J Neurosci 7: 369-379.

40. Kim ID, Shin JH, Lee HK, et al. (2012) Intranasal delivery of HMGB1-binding heptamer peptide confers a robust neuroprotection in the postischemic brain. Neurosci Lett 525: 179-183.

41. Sun Q, Wang F, Li W, et al. (2013) Glycyrrhizic acid confers neuroprotection after subarachnoid hemorrhage via inhibition of high mobility group box-1 protein: a hypothesis for novel therapy of subarachnoid hemorrhage. Med Hypotheses 81: 681-685.

42. Zhang J, Wu Y, Weng Z, et al. (2014) Glycyrrhizin protects brain against ischemia-reperfusion injury in mice through HMGB1-TLR4-IL-17A signaling pathway. Brain Res 1582: 176-186.

43. Yang QW, Xiang J, Zhou Y, et al. (2010) Targeting HMGB1/TLR4 signaling as a novel approach to treatment of cerebral ischemia. Front Biosci 2: 1081-1091.

44. Laird MD, Shields JS, Sukumari-Ramesh S, et al. (2014) High mobility group box protein-1 promotes cerebral edema after traumatic brain injury via activation of toll-like receptor 4. Glia 62: 26-38.

45. Maroso M, Balosso S, Ravizza T, et al. (2010) Toll-like receptor 4 and high-mobility group box-1 are involved in ictogenesis and can be targeted to reduce seizures. Nat Med 16: 413-419.

Copyright Info: © 2015, Fulton T. Crews, et al., licensee AIMS Press. This is an open access article distributed under the terms of the Creative Commons Attribution Licese (http://creativecommons.org/licenses/by/4.0)

Download full text in PDF

Export Citation

Article outline

Show full outline